Biond Biologics Ltd.

Biond Biologics Ltd. is a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment, utilizing advanced biotechnological approaches to enhance clinical efficacy and reduce side effects in patients. Founded in 2016 and headquartered in Nahariyya, Israel, Biond Biologics specializes in the creation of groundbreaking biologics aimed at treating various cancers. The company has successfully raised USD 15 mn in Series C funding as of November 3, 2021, led by Deep Insight, with participation from Harel Insurance Investments and Heritage Group.

The company has completed a total of 2 deals to date. Biond Biologics specializes in the development of innovative therapies aimed at addressing various forms of cancer. The company's core offerings focus on breakthrough biologics that utilize advanced biotechnology to target and combat cancerous cells, thereby enhancing treatment efficacy and minimizing side effects. These products are designed for use in clinical settings and are intended for oncologists, healthcare providers, and hospitals that are looking for cutting-edge treatment options for their patients.

Biond's therapies are currently marketed across multiple geographical regions, including North America, Europe, and select markets in Asia, catering to a diverse client base of healthcare institutions and research facilities dedicated to cancer treatment and research. Biond Biologics operates on a revenue model that primarily involves partnerships with healthcare institutions and pharmaceutical companies for the distribution and application of its therapeutic products. Revenue is generated through direct sales to hospitals and clinics, as well as potential licensing agreements that facilitate the use of Biond's innovative therapies in broader healthcare settings. The pricing structure typically reflects the advanced nature of the products, with flagship offerings commanding premium pricing in line with their unique therapeutic capabilities.

Transactions are structured to enable seamless integration into existing treatment protocols, with an emphasis on providing high-value solutions to healthcare providers focused on improving patient outcomes in oncology. Biond Biologics plans to leverage its recent Series C funding of USD 15 mn to support the advancement of its pipeline of cancer therapies, with new products expected to be launched in the coming years. The company is also seeking to expand its presence in emerging markets in Asia and South America by 2023, enhancing distribution and partnerships in these regions. The Series C funding will be instrumental in facilitating these strategic initiatives, enabling Biond to further its mission of providing effective cancer treatments worldwide.